Enhanced therapeutic effect of transcatheter arterial chemoembolization combined with radioactive I‑125 seed implantation on liver cancer

Liu,Wenbao; Xiu,Nanguang; Zhao,Jinwei; Zhao,Lianhao

doi:10.3892/ol.2020.11765

Enhanced therapeutic effect of transcatheter arterial chemoembolization combined with radioactive I‑125 seed implantation on liver cancer

Authors:
- Wenbao Liu
- Nanguang Xiu
- Jinwei Zhao
- Lianhao Zhao
View Affiliations

Affiliations: Department of Intervention Therapy, Laiyang Central Hospital, Yantai, Shandong 265200, P.R. China
Published online on: June 24, 2020 https://doi.org/10.3892/ol.2020.11765
Pages: 2493-2498

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to evaluate the therapeutic effect of transcatheter arterial chemoembolization (TACE) combined with radioactive I‑125 (iodine‑125) seed implantation on liver cancer. A total of 38 liver cancer patients in the combined treatment group were treated with lobaplatin‑TACE combined with radioactive I‑125 seed implantation, while 45 patients in the TACE group were treated only with lobaplatin‑TACE. Patients were followed up for survival time, and the liver function, change in α‑fetoprotein (AFP) and side effects were evaluated. The average survival time of patients was 6.1 months in the TACE group and 8.2 months in the combined treatment group, and the overall survival was significantly different between the two groups (P<0.05). The response rate of lesions in the combined treatment group was superior to that observed in the TACE group, and the change in AFP in the TACE group was smaller than that in the combined treatment group. Improvement in the effects on most liver function indices in the combined treatment group were better than those in the TACE group. In addition, there were no differences in the side effects experienced between the two groups. Results of this study indicate that the effect of TACE combined with radioactive I‑125 seed implantation is superior to that of TACE alone for the treatment of liver cancer, which can further benefit patients.

View Figures

View References

1	Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005. View Article : Google Scholar : PubMed/NCBI
2	Tang ZY, Ye SL, Liu YK, Qin LX, Sun HC, Ye QH, Wang L, Zhou J, Qiu SJ, Li Y, et al: A decade's studies on metastasis of hepatocellular carcinoma. J Cancer Res Clin Oncol. 130:187–196. 2004. View Article : Google Scholar : PubMed/NCBI
3	Bruix J and Sherman M; Practice Guidelines Committee, American Association for the Study of Liver Diseases, : Management of hepatocellular carcinoma. Hepatology. 42:1208–1236. 2005. View Article : Google Scholar : PubMed/NCBI
4	Forner A, Llovet JM and Bruix J: Hepatocellular carcinoma. Lancet. 379:1245–1255. 2012. View Article : Google Scholar : PubMed/NCBI
5	Shi M, Lu LG, Fang WQ, Guo RP, Chen MS, Li Y, Luo J, Xu L, Zou RH, Lin XJ and Zhang YQ: Roles played by chemolipiodolization and embolization in chemoembolization for hepatocellular carcinoma: Single-blind, randomized trial. J Natl Cancer Inst. 105:59–68. 2013. View Article : Google Scholar : PubMed/NCBI
6	Llovet JM and Bruix J: Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology. 37:429–442. 2003. View Article : Google Scholar : PubMed/NCBI
7	Raoul JL, Forner A, Bolondi L, Cheung TT, Kloeckner R and de Baere T: Updated use of TACE for hepatocellular carcinoma treatment: How and when to use it based on clinical evidence. Cancer Treat Rev. 72:28–36. 2019. View Article : Google Scholar : PubMed/NCBI
8	McKeage MJ: Lobaplatin: A new antitumour platinum drug. Expert Opin Investig Drugs. 10:119–128. 2001. View Article : Google Scholar : PubMed/NCBI
9	Dawson LA and Lawrence TS: The role of radiotherapy in the treatment of liver metastases. Cancer J. 10:139–144. 2004. View Article : Google Scholar : PubMed/NCBI
10	Li C, Zhang F, Zhang W, Zhang L, Huang Z and Wu P: Feasibility of (125)I brachytherapy combined with sorafenib treatment in patients with multiple lung metastases after liver transplantation for hepatocellular carcinoma. J Cancer Res Clin Oncol. 136:1633–1640. 2010. View Article : Google Scholar : PubMed/NCBI
11	Zhang L, Mu W, Hu CF and Huang XQ: Treatment of portal vein tumor thrombus using ¹²⁵Iodine seed implantation brachytherapy. World J Gastroenterol. 16:4876–4879. 2010. View Article : Google Scholar : PubMed/NCBI
12	Meng N, Jiang YL, Wang JJ, Ran WQ, Yuan HS, Qu A, Jiang P and Yang RJ: Permanent implantation of iodine-125 seeds as a salvage therapy for recurrent head and neck carcinoma after radiotherapy. Cancer Invest. 30:236–242. 2012. View Article : Google Scholar : PubMed/NCBI
13	Wang KX, Jin ZD, Du YQ, Zhan XB, Zou DW, Liu Y, Wang D, Chen J, Xu C and Li ZS: EUS-guided celiac ganglion irradiation with iodine-125 seeds for pain control in pancreatic carcinoma: A prospective pilot study. Gastrointest Endosc. 76:945–952. 2012. View Article : Google Scholar : PubMed/NCBI
14	Litière S, Collette S, de Vries EG, Seymour L and Bogaerts J: RECIST-learning from the past to build the future. Nat Rev Clin Oncol. 14:187–192. 2017. View Article : Google Scholar : PubMed/NCBI
15	Alterovitz R, Pouliot J, Taschereau R, Hsu IC and Goldberg K: Simulating needle insertion and radioactive seed implantation for prostate brachytherapy. Stud Health Technol Inform. 94:19–25. 2003.PubMed/NCBI
16	Wang S, Shi G and Meng X: Clinical curative effect of percutaneous vertebroplasty combined with 125I-seed implantation in treating spinal metastatic tumor. Pak J Pharm Sci. 28:S1039–S1042. 2015.
17	Lazarescu GR and Battista JJ: Analysis of the radiobiology of ytterbium-169 and iodine-125 permanent brachytherapy implants. Phys Med Biol. 42:1727–1736. 1997. View Article : Google Scholar : PubMed/NCBI
18	Zhuang HQ, Wang JJ, Liao AY, Wang JD and Zhao Y: The biological effect of 125I seed continuous low dose rate irradiation in CL187 cells. J Exp Clin Cancer Res. 28:122009. View Article : Google Scholar : PubMed/NCBI
19	Nakamura H, Yasui Y, Saito N, Tachibana A, Komatsu K and Ishizaki K: DNA repair defect in AT cells and their hypersensitivity to low-dose-rate radiation. Radiat Res. 165:277–282. 2006. View Article : Google Scholar : PubMed/NCBI
20	Meigooni AS and Nath R: Response to Comment on ‘Dosimetry of interstitial brachytherapy sources: Recommendation of the AAPM Radiation therapy committee task group 43′ [Med. Phys. 26, 2514 (1999)]. American association of physicists in medicine. Med Phys. 27:2652000. View Article : Google Scholar : PubMed/NCBI
21	Chen K, Xia Y, Wang H, Xiao F, Xiang G and Shen F: Adjuvant iodine-125 brachytherapy for hepatocellular carcinoma after complete hepatectomy: A randomized controlled trial. PLoS One. 8:e573972013. View Article : Google Scholar : PubMed/NCBI
22	Nag S, DeHaan M, Scruggs G, Mayr N and Martin EW: Long-term follow-up of patients of intrahepatic malignancies treated with iodine-125 brachytherapy. Int J Radiat Oncol Biol Phys. 64:736–744. 2006. View Article : Google Scholar : PubMed/NCBI
23	Martinez-Monge R, Nag S, Nieroda CA and Martin EW: Iodine-125 brachytherapy in the treatment of colorectal adenocarcinoma metastatic to the liver. Cancer. 85:1218–1225. 1999. View Article : Google Scholar : PubMed/NCBI
24	Zhang FJ, Li CX, Wu PH, Li K, Huang JH, Fan WJ, Zhang L, Gu YK, Lu MJ, Wu YX and Wang JJ: Radioactive seed 125I implantation in treating recurrence and metastasis after liver transplantation in hepatoma. Zhonghua Yi Xue Za Zhi. 87:956–959. 2007.(In Chinese). PubMed/NCBI
25	Zhang FJ, Li CX, Zhang L, Wu PH, Jiao DC and Duan GF: Short-to mid-term evaluation of CT-guided 125I brachytherapy on intra-hepatic recurrent tumors and/or extra-hepatic metastases after liver transplantation for hepatocellular carcinoma. Cancer Biol Ther. 8:585–590. 2009. View Article : Google Scholar : PubMed/NCBI
26	Zhang FJ, Wu PH, Zhao M, Huang JH, Fan WJ, Gu YK, Liu J, Zhang L and Lu MJ: CT guided radioactive seed 125I implantation in treatment of pancreatic cancer. Zhonghua Yi Xue Za Zhi. 86:223–227. 2006.(In Chinese). PubMed/NCBI